CIS
NBIX icon

Capital International Sarl’s Neurocrine Biosciences NBIX Stock Holding History

Capital International Sarl’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,934
Closed -$856K – 250
2020
Q4 		$856K Hold
8,934
– – 0.09% 174
2020
Q3 		$859K Sell
8,934
-4,029
-31% -$466K 0.11% 151
2020
Q2 		$1.58M Buy
12,963
+842
+7% +$93K 0.21% 103
2020
Q1 		$1.05M Sell
12,121
-11,979
-50% -$1.17M 0.19% 107
2019
Q4 		$2.59M Hold
24,100
– – 0.4% 82
2019
Q3 		$2.17M Buy
+24,100
New +$2.25M 0.37% 81

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Capital International Sarl's NBIX Position: Q1 2021 in Review

Capital International Sarl sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 8,934 shares — an estimated $856K sold.

Capital International Sarl first reported a position in NBIX in Q3 2019 and held it in 6 quarters. The position peaked at $2.59M in Q4 2019. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

  • Capital International Sarl reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
  • Capital International Sarl sold 8,934 Neurocrine Biosciences shares in Q1 2021, an estimated $856K.
  • Capital International Sarl first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 6 quarters.
  • Capital International Sarl's Neurocrine Biosciences position peaked at $2.59M in Q4 2019.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on Capital International Sarl's 13F filing for Q1 2021, filed 14 May 2021.